> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly’s Retevmo Hits Phase 3 Trial PFS Endpoint
- URL: https://www.fdaweb.com/lillys-retevmo-hits-phase-3-trial-pfs-endpoint/
- Published: 2023-08-23T12:00:00.000Z
- Updated: 2026-09-14T18:52:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155167

Lilly says its Retevmo (selpercatinib) met the primary endpoint of progression-free survival in the LIBRETTO-531 study evaluating the drug versus doctors’ choice of approved multikinase inhibitors cabozantinib (Exelixis’ Cabometyx) or vandetanib (Sanofi’s Caprelsa) as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer. A company [statement](http://investor.lilly.com/news-releases/news-release-details/lillys-retevmor-selpercatinib-demonstrates-superior-progression?ref=fdaweb.com) describes Retevmo as a highly selective and potent RET kinase inhibitor with central nervous system activity. It is approved by FDA to treat certain cancers caused by abnormal RET genes in some children and adults.